Safety and Efficacy of the Sirolimus Gel for TSC Patients With Facial Skin Lesions in a Long-Term, Open-Label, Extension, Uncontrolled Clinical Trial

[1]  M. Wataya-Kaneda,et al.  Efficiency of sirolimus delivery to the skin is dependent on administration route and formulation. , 2019, Journal of dermatological science.

[2]  J. Slopis,et al.  Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial , 2018, JAMA dermatology.

[3]  H. Nagai,et al.  Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial , 2018, JAMA dermatology.

[4]  M. Wataya-Kaneda,et al.  Uncoupling of ER/Mitochondrial Oxidative Stress in mTORC1 Hyperactivation-Associated Skin Hypopigmentation. , 2017, The Journal of investigative dermatology.

[5]  T. Yoshimori,et al.  Dysregulation of autophagy in melanocytes contributes to hypopigmented macules in tuberous sclerosis complex. , 2017, Journal of dermatological science.

[6]  M. Wataya-Kaneda,et al.  Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex: A Randomized Clinical Trial , 2017, JAMA dermatology.

[7]  J. French,et al.  Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study , 2016, The Lancet.

[8]  E. Thiele,et al.  Tuberous Sclerosis Complex , 2019, Harper's Textbook of Pediatric Dermatology.

[9]  M. Wataya-Kaneda,et al.  Clinical and Histologic Analysis of the Efficacy of Topical Rapamycin Therapy Against Hypomelanotic Macules in Tuberous Sclerosis Complex. , 2015, JAMA dermatology.

[10]  E. Roach,et al.  Tuberous sclerosis complex. , 2015, Handbook of clinical neurology.

[11]  M. Wataya-Kaneda,et al.  Dermatologic and dental aspects of the 2012 International Tuberous Sclerosis Complex Consensus Statements. , 2014, JAMA dermatology.

[12]  M. Wataya-Kaneda,et al.  First left–right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex , 2013, The British journal of dermatology.

[13]  Hope Northrup,et al.  Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. , 2013, Pediatric neurology.

[14]  D. Krueger,et al.  Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference , 2013, Pediatric neurology.

[15]  M. Wataya-Kaneda,et al.  Trends in the Prevalence of Tuberous Sclerosis Complex Manifestations: An Epidemiological Study of 166 Japanese Patients , 2013, PloS one.

[16]  David Chen,et al.  Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial , 2013, The Lancet.

[17]  E. Thiele,et al.  Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial , 2013, The Lancet.

[18]  M. Wataya-Kaneda,et al.  A topical combination of rapamycin and tacrolimus for the treatment of angiofibroma due to tuberous sclerosis complex (TSC): a pilot study of nine Japanese patients with TSC of different disease severity , 2011, The British journal of dermatology.

[19]  J. Macgregor,et al.  Dramatic improvement of facial angiofibromas in tuberous sclerosis with topical rapamycin: optimizing a treatment protocol. , 2011, Archives of dermatology.

[20]  J. Krischer,et al.  Efficacy and safety of sirolimus in lymphangioleiomyomatosis. , 2011, The New England journal of medicine.

[21]  A. Ganesan,et al.  WIPI1 Coordinates Melanogenic Gene Transcription and Melanosome Formation via TORC1 Inhibition* , 2011, The Journal of Biological Chemistry.

[22]  J. Teng,et al.  Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis. , 2010, Archives of dermatology.

[23]  B. Rutkowski,et al.  Rapamycin as a therapy of choice after renal transplantation in a patient with tuberous sclerosis complex. , 2009, Transplantation proceedings.

[24]  L. French,et al.  The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis , 2008, The British journal of dermatology.

[25]  R. Schwartz,et al.  Tuberous sclerosis complex: advances in diagnosis, genetics, and management. , 2007, Journal of the American Academy of Dermatology.

[26]  K. Yoshikawa,et al.  A Case of Tuberous Sclerosis with a Giant Angiofibroma , 1997, The Journal of dermatology.

[27]  A. Fyer,et al.  The cutaneous features of tuberous sclerosis: a population study , 1996, The British journal of dermatology.

[28]  A Y Finlay,et al.  The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use , 1995, The British journal of dermatology.

[29]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.